▶ Full Post Text
# Adia Med Kicks Off Recruitment Today for Innovative Autism Stem Cell Study
Winter Park, Florida--(Newsfile Corp. - January 13, 2026) - ADIA Nutrition Inc. (OTCQB: ADIA), today announced that its subsidiary, Adia Med of Winter Park, LLC., has officially begun the recruitment process for a groundbreaking clinical study evaluating the potential benefits of stem cell therapy in children with Autism Spectrum Disorder (ASD).
The 24-month randomized interventional study, officially titled "Adia MED of Winter Park LLC Autism Spectrum Disorder Research Study" and listed on [ClinicalTrials.gov](http://ClinicalTrials.gov) (NCT07304440), is being conducted at Adia Med's clinic in Winter Park, Florida.
Adia MED of Winter Park LLC Autism Spectrum Disorder Research Study: [https://clinicaltrials.gov/study/NCT07304440](https://api.newsfilecorp.com/redirect/oP7Bpt05j3)
[](https://images.newsfilecorp.com/files/10520/280212_adiaasd.jpg)
Adia Med ASD Study Recruiting Status
[ClinicalTrials.gov](http://ClinicalTrials.gov) has provided receipt confirmation that the study is now in recruiting status, and it should appear publicly in recruiting status on the site within the next few days.
The trial aims to enroll approximately 100 children ages 3-12 with a confirmed ASD diagnosis. This study investigates whether combining AdiaVita-Adia Med's proprietary umbilical cord blood-derived stem cell and exosome product-with glutathione therapy provides greater improvement in autism symptoms compared to glutathione therapy alone. Participants will be randomly assigned to one of two groups for the initial three-month phase:
* One group will receive glutathione only.
* The other will receive glutathione plus monthly intravenous infusions of AdiaVita.
Success will be assessed over the full 24 months using the Autism Treatment Evaluation Checklist (ATEC), completed by parents as well as therapists or teachers. The primary outcome is the change in total ATEC scores at six months, with additional focus on safety, tolerability, quality of life, and overall well-being through regular clinic visits, physical exams, blood tests, and adverse event monitoring. After the initial phase, children in the glutathione-only group will have the opportunity to cross over and receive AdiaVita infusions at no additional cost.
In the last year of its operations, Adia Med of Winter Park has observed tremendous results from its one-off studies with children that have ASD.
"Launching recruitment for this important study marks a significant milestone in our commitment to advancing regenerative therapies for autism," said Larry Powalisz, CEO of Adia Nutrition Inc. "We are excited to explore the potential of AdiaVita combined with glutathione to support families affected by ASD and contribute meaningful data to the scientific community."
**Participation Details and Costs**
Participation in the study is completely voluntary, and families may withdraw at any time without penalty (though fees already paid for completed procedures are non-refundable). There is a one-time fixed participation fee of $12,000 that covers:
* All treatments and procedures during the initial three-month Phase One (regardless of which group the child is randomized to)
* All required clinic visits, monitoring, physical exams, blood tests, and safety assessments throughout the full 24-month study
* Entry into the optional Phase II crossover extension (including AdiaVita infusions) at no additional cost for families initially assigned to the glutathione-only group.
No monetary incentives or compensation are provided to participants. Interested families are encouraged to contact Adia Med directly for eligibility screening, a full breakdown of what the fee covers, payment options, and additional information.
[https://finance.yahoo.com/news/adia-med-kicks-off-recruitment-151600505.html](https://finance.yahoo.com/news/adia-med-kicks-off-recruitment-151600505.html)